Physician profile
Ingrid E Roseborough
NPI 1972636272
$32,788.36
in general payments reported to CMS, 2019-2025
30 companies · $19K in 2025
The $19K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,278 · 2020: $346 · 2021: $1,190 · 2022: $1,408 · 2023: $3,882 · 2024: $5,625 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $6,614 · Consulting Fee: $3,745 · Education: $308 · Travel and Lodging: $8.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,890.00 |
| Food and Beverage | $6,614.20 |
| Consulting Fee | $3,745.00 |
| Education | $307.88 |
| Travel and Lodging | $8.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19,760.94 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $3,688.99 | 2023-2025 | Zoryve |
| Abbvie INC. | $1,874.30 | 2019-2025 | Rinvoq, Botox, Skyrizi |
| Lilly USA, LLC | $1,076.64 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $946.61 | 2019-2025 | Nemluvio, Epsolay |
| Genzyme Corporation | $897.53 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $655.32 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $625.69 | 2019-2025 | Winlevi, Absorica Ld |
| Leo Pharma INC. | $581.64 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $518.19 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $398.23 | 2019-2024 | Tremfya, Simponi, Remicade |
| E.R. Squibb & Sons, L.L.C. | $339.58 | 2023-2024 | Sotyktu |
| Amgen INC. | $263.94 | 2019-2024 | Otezla |
| Organon LLC | $240.93 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $182.92 | 2020-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $155.38 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Almirall LLC | $151.39 | 2019-2024 | Klisyri, Seysara |
| Biofrontera INC. | $112.23 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $57.50 | 2020-2022 | |
| Dermavant Sciences, INC. | $50.79 | 2023 | Vtama |
| Janssen Scientific Affairs, LLC | $44.43 | 2019-2021 | |
| Aclaris Therapeutics, INC. | $23.86 | 2019 | |
| Verrica Pharmaceuticals INC. | $23.30 | 2025 | Ycanth |
| Dermira, INC. | $21.76 | 2019 | |
| Mission Pharmacal Company | $19.55 | 2019 | |
| Botanix Sb INC | $17.39 | 2025 | Sofdra |
| Epi Health, LLC | $16.97 | 2019 | |
| Convatec INC. | $15.71 | 2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $13.74 | 2019 | |
| Dusa Pharmaceuticals, INC. | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Roseborough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.